Form 4 for VERA Vera Therapeutics, Inc.

Accepted 2023-03-07 00:00:00 ET · period of report 2023-03-03 · accession 0001209191-23-016702 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2023-03-07	2023-03-03	VERA	SEIDENBERG BETH C	Dir	P - Purchase	$7.25	+1,000	1.69M	+0.1%	+$7,250

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Class A Common Stock	2023-03-03	P	A	1,000	$7.25	1,689,380	I See footnote	—	—	(F1) The shares were purchased as follows: 967 shares by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 33 shares by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI and XVI Founders is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI and XVI Founders. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI and XVI Founders except to the extent of their pecuniary interest therein. (F2) Represents weighted average purchase price. The shares were purchased at prices ranging from $7.23 to $7.25. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price. (F3) Consists of 1,633,464 shares of Class A Common Stock held by KPCB XVI and 55,916 shares of Class A Common Stock held by XVI Founders.